Literature DB >> 21258878

Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up.

Margherita Nannini1, Guido Biasco, Maria Caterina Pallotti, Monica Di Battista, Donatella Santini, Paola Paterini, Alessandra Maleddu, Anna Mandrioli, Cristian Lolli, Maristella Saponara, Valerio Di Scioscio, Maurizio Zompatori, Fausto Catena, Pietro Fusaroli, Angelo Paolo Dei Tos, Maria Abbondanza Pantaleo.   

Abstract

In practice, relapses of gastrointestinal stromal tumours after long time of surgical resection occur. However, few published data are available for duration, intensity and imaging sources of follow-up in radically excised patients with localized disease. Therefore, every single institution chooses the surveillance schedule according to its experience. The aim of this study was to describe the late recurrences of disease 5 years after the primary tumour's excision in a series of patients with recurrent GIST from our institution. We retrospectively reviewed 42 patients with "recurrent" GIST, collected since 2001. Ten patients were always followed at our institution, and 32 patients came to our attention at the time of recurrence. The analysed series were divided into two groups: patients who developed recurrence before 5 years and patients who developed recurrence 5 years after the primary tumour's excision. Among 42 patients, 36 patients developed the recurrence within 5 years of the primary tumour excision, whereas 6 patients developed the recurrence 5 years after primary tumour excision diagnosed during follow-up or casually for other reasons. All patients had distant recurrence, involving liver and peritoneum, whereas no local relapse was observed. These patients were heterogeneous in primary tumour site, risk classification and molecular analysis. Duration of the follow-up for radically excised patients with GIST remains still unsettled; however, the integration of every clinical, pathological and molecular parameter is essential to optimize the duration and intensity of the follow-up for each single patient.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21258878     DOI: 10.1007/s12032-010-9806-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  32 in total

1.  Increased risk of second primary cancers after a diagnosis of melanoma.

Authors:  Porcia T Bradford; D Michal Freedman; Alisa M Goldstein; Margaret A Tucker
Journal:  Arch Dermatol       Date:  2010-03

2.  Multiple gastrointestinal stromal tumors: Clinicopathologic and genetic analysis of 12 patients.

Authors:  Dae Young Kang; Cheol Keun Park; Jong Sang Choi; So Young Jin; Hyun Jung Kim; Mee Joo; Mi Seon Kang; Woo Sung Moon; Ki Jung Yun; Eun Sil Yu; Haeyun Kang; Kyoung-Mee Kim
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

3.  Dormancy of mammary carcinoma after mastectomy.

Authors:  T G Karrison; D J Ferguson; P Meier
Journal:  J Natl Cancer Inst       Date:  1999-01-06       Impact factor: 13.506

4.  KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.

Authors:  Christopher L Corless; Laura McGreevey; Andrea Haley; Ajia Town; Michael C Heinrich
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

5.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Robert G Maki; Christopher L Corless; Cristina R Antonescu; Amy Harlow; Diana Griffith; Ajia Town; Arin McKinley; Wen-Bin Ou; Jonathan A Fletcher; Christopher D M Fletcher; Xin Huang; Darrel P Cohen; Charles M Baum; George D Demetri
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

6.  Contralateral breast cancers following treatment for initial breast cancers in women.

Authors:  R G Parker; P Grimm; J E Enstrom
Journal:  Am J Clin Oncol       Date:  1989-06       Impact factor: 2.339

7.  Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

Authors:  Ronald P Dematteo; Jason S Gold; Lisa Saran; Mithat Gönen; Kui Hin Liau; Robert G Maki; Samuel Singer; Peter Besmer; Murray F Brennan; Cristina R Antonescu
Journal:  Cancer       Date:  2008-02-01       Impact factor: 6.860

Review 8.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  Multicentric sporadic gastrointestinal stromal tumors (GISTs) of the stomach with distinct clonal origin: differential diagnosis to familial and syndromal GIST variants and peritoneal metastasis.

Authors:  Florian Haller; Hans-Jürgen Schulten; Thomas Armbrust; Claus Langer; Bastian Gunawan; László Füzesi
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

View more
  1 in total

1.  Effectiveness of radiation therapy in GIST: A case report.

Authors:  Joshua Halpern; Yong-June Kim; Rumana Sultana; Gina Villani
Journal:  J Gastrointest Oncol       Date:  2012-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.